Literature DB >> 3241228

Contribution of bradykinin to maintenance of blood pressure and renal blood flow in anaesthetized spontaneously hypertensive rats.

M Seino1, K Abe, N Nushiro, K Omata, Y Kasai, K Yoshinaga.   

Abstract

We used a newly synthesized competitive antagonist of bradykinin (B 4147) to determine whether bradykinin contributes to the maintenance of blood pressure and renal blood flow in anaesthetized Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). The injection of B 4147 (50 micrograms, intravenously) caused an increase in blood pressure and a decrease in renal blood flow in both strains. However, the magnitude in the change in blood pressure was significantly lower in SHR than in WKY. The reduction of renal blood flow was greater in WKY than in SHR, but there was no significant difference in the basal renal blood flow. These results indicate that bradykinin contributes to the maintenance of blood pressure and renal blood flow in both strains. However, bradykinin antagonist produced a more prominent systemic effect in WKY than in SHR. This suggests that a deficiency in the bradykinin system in SHR contributes to the development or the maintenance of hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3241228     DOI: 10.1097/00004872-198812040-00126

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

1.  Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages.

Authors:  K J Wirth; W Linz; G Wiemer; B A Schölkens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

2.  Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats.

Authors:  P Madeddu; V Anania; P P Parpaglia; M P Demontis; M V Varoni; G Pisanu; C Troffa; G Tonolo; N Glorioso
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

3.  Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.

Authors:  T Sakamoto; C Chen; M F Lokhandwala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.